Basic Information
| LncRNA/CircRNA Name | lncRNA-PRAL |
| Synonyms | PRAL, lncRNA-PRAL |
| Region | GRCh38_17:6772831-6776116 |
| Ensemble | ENSG00000279296 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot etc. |
| Sample | HCC tissues |
| Expression Pattern | down-regulated |
| Function Description | We found that lncRNA-PRAL could inhibit HCC growth and induce apoptosis in vivo and in vitro through p53. Subsequent investigations indicated that the three stem-loop motifs at the 5' end of lncRNA-PRAL facilitated the combination of HSP90 and p53, and thus competitively inhibited the MDM2-dependent p53 ubiquitination, resulting in the enhanced p53 stability. Additionally, in vivo lncRNA-PRAL delivery efficiently reduced the intrinsic tumors, indicating its potential therapeutic application. |
| Pubmed ID | 26663434 |
| Year | 2015 |
| Title | Systemic genome screening identified the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma |
External Links
| Links for lncRNA-PRAL | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |